Kareus Therapeutics

Kareus initiates phase I trial in Alzheimer’s disease

Friday, January 4, 2013

Kareus Therapeutics, a private biotechnology company focused on unmet treatment of age-related and chronic diseases, has initiated a phase I clinical study following the Investigational New Drug (IND) approval from the FDA for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer’s disease using Kareus’ proprietary bioenergetics and KARLECT platforms.

[Read More]

Quintiles invests in Swiss biotech Kareus

Tuesday, June 14, 2011

In further evidence of a shift toward more fundamental risk-sharing in drug development between biopharmaceutical companies and CROs, Quintiles is making a significant investment in Swiss biotech Kareus Therapeutics as part of a broad strategic alliance to move two of Kareus’ pre-clinical programs through clinical trials, according to PharmaTimes.

[Read More]